–
Статьи в журналах
-
- 2024 Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Ou
- Rastogi Priya, O'Shaughnessy Joyce, Martin Miguel, Boyle Frances, Cortes Javier, Rugo Hope S., Goetz Matthew P., Hamilton Erika P., Huang Chiun-Sheng, Senkus Elzbieta, Tryakin Alexey, Cicin Irfan, Testa Laura, Neven Patrick, Huober Jens, Shao Zhimin, Wei Ran, André Valérie, Munoz Maria, San Antonio Belen, Shahir Ashwin, Harbeck Nadia, Johnston Stephen
- в журнале Journal of Clinical Oncology, издательство American Society of Clinical Oncology (United States) DOI